Testing for the Use of Biologic Therapeutics for the Treatment of Inflammatory Disorders 2.02.47
Effective date
Nov 20, 2025
Identified
Jun 20, 2026
Summary
Procise ADL, Procise IFX, PredictrPK IFX, ADALX, Anser ADA, Anser IFX, Anser UST and Anser VDZ are considered investigational when used to measure serum drug or antibody levels for biologic therapies. Tests that predict response or non-response to biologic therapies, such as PrismRA alone or as a combination test, are also considered investigational. Code 0456U was deleted in the 11/20/25 annual review.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.